301 related articles for article (PubMed ID: 31756985)
1. CGRP Signaling via CALCRL Increases Chemotherapy Resistance and Stem Cell Properties in Acute Myeloid Leukemia.
Gluexam T; Grandits AM; Schlerka A; Nguyen CH; Etzler J; Finkes T; Fuchs M; Scheid C; Heller G; Hackl H; Harrer N; Sill H; Koller E; Stoiber D; Sommergruber W; Wieser R
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31756985
[TBL] [Abstract][Full Text] [Related]
2. Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells.
Larrue C; Guiraud N; Mouchel PL; Dubois M; Farge T; Gotanègre M; Bosc C; Saland E; Nicolau-Travers ML; Sabatier M; Serhan N; Sahal A; Boet E; Mouche S; Heydt Q; Aroua N; Stuani L; Kaoma T; Angenendt L; Mikesch JH; Schliemann C; Vergez F; Tamburini J; Récher C; Sarry JE
Nat Commun; 2021 Jan; 12(1):422. PubMed ID: 33462236
[TBL] [Abstract][Full Text] [Related]
3. CALCRL induces resistance to daunorubicin in acute myeloid leukemia cells through upregulation of XRCC5/TYK2/JAK1 pathway.
Tang S; Li S; Shi X; Sheng L; Mu Q; Wang Y; Zhu H; Xu K; Zhou M; Xu Z; Wu A; Ouyang G
Anticancer Drugs; 2024 Feb; 35(2):163-176. PubMed ID: 37948318
[TBL] [Abstract][Full Text] [Related]
4. The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.
Angenendt L; Bormann E; Pabst C; Alla V; Görlich D; Braun L; Dohlich K; Schwöppe C; Bohlander SK; Arteaga MF; Wethmar K; Hartmann W; Angenendt A; Kessler T; Mesters RM; Stelljes M; Rothenberg-Thurley M; Spiekermann K; Hébert J; Sauvageau G; Valk PJM; Löwenberg B; Serve H; Müller-Tidow C; Lenz G; Wörmann BJ; Sauerland MC; Hiddemann W; Berdel WE; Krug U; Metzeler KH; Mikesch JH; Herold T; Schliemann C
Leukemia; 2019 Dec; 33(12):2830-2841. PubMed ID: 31182782
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of CALCRL-associated prognostic genes in acute myeloid leukemia.
Huang Z; Zhang H; Xing C; Zhang L; Zhu H; Deng Z; Yin L; Dong E; Wang C; Peng H
Gene; 2022 Jan; 809():146009. PubMed ID: 34655717
[TBL] [Abstract][Full Text] [Related]
6. STC1 interference on calcitonin family of receptors signaling during osteoblastogenesis via adenylate cyclase inhibition.
Terra SR; Cardoso JC; Félix RC; Martins LA; Souza DO; Guma FC; Canário AV; Schein V
Mol Cell Endocrinol; 2015 Mar; 403():78-87. PubMed ID: 25591908
[TBL] [Abstract][Full Text] [Related]
7. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular effects of exogenous adrenomedullin and CGRP in Ramp and Calcrl deficient mice.
Pawlak JB; Wetzel-Strong SE; Dunn MK; Caron KM
Peptides; 2017 Feb; 88():1-7. PubMed ID: 27940069
[TBL] [Abstract][Full Text] [Related]
10. The CGRP Receptor Antagonist MK0974 Induces EVI1
Suekane A; Ichikawa T; Saito Y; Nakahata S; Morishita K
Anticancer Res; 2022 Oct; 42(10):4743-4752. PubMed ID: 36191988
[TBL] [Abstract][Full Text] [Related]
11. Calcitonin receptor-like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML.
Angenendt L; Wöste M; Mikesch JH; Arteaga MF; Angenendt A; Sandmann S; Berdel WE; Lenz G; Dugas M; Meshinchi S; Schliemann C; Rössig C
Blood Adv; 2021 Nov; 5(21):4413-4421. PubMed ID: 34559198
[TBL] [Abstract][Full Text] [Related]
12. Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors.
Venton G; Pérez-Alea M; Baier C; Fournet G; Quash G; Labiad Y; Martin G; Sanderson F; Poullin P; Suchon P; Farnault L; Nguyen C; Brunet C; Ceylan I; Costello RT
Blood Cancer J; 2016 Sep; 6(9):e469. PubMed ID: 27611922
[TBL] [Abstract][Full Text] [Related]
13. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
[TBL] [Abstract][Full Text] [Related]
14. Calcitonin Gene-Related Peptide Rescues Proximity Associations of Its Receptor Components, Calcitonin Receptor-Like Receptor and Receptor Activity-Modifying Protein 1, in Rat Uterine Artery Smooth Muscle Cells Exposed to Tumor Necrosis Factor Alpha.
Dong Y; Chauhan M; Belfort M; Yallampalli C
Biol Reprod; 2016 Dec; 95(6):126. PubMed ID: 27784654
[TBL] [Abstract][Full Text] [Related]
15. Gene expression changes contribute to stemness and therapy resistance of relapsed acute myeloid leukemia: roles of SOCS2, CALCRL, MTSS1, and KDM6A.
Grandits AM; Wieser R
Exp Hematol; 2021 Jul; 99():1-11. PubMed ID: 34029637
[TBL] [Abstract][Full Text] [Related]
16. All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia.
Nguyen CH; Bauer K; Hackl H; Schlerka A; Koller E; Hladik A; Stoiber D; Zuber J; Staber PB; Hoelbl-Kovacic A; Purton LE; Grebien F; Wieser R
Cell Death Dis; 2019 Dec; 10(12):944. PubMed ID: 31822659
[TBL] [Abstract][Full Text] [Related]
17. Targeting murine leukemic stem cells by antibody functionalized mesoporous silica nanoparticles.
Mandal T; Beck M; Kirsten N; Lindén M; Buske C
Sci Rep; 2018 Jan; 8(1):989. PubMed ID: 29343865
[TBL] [Abstract][Full Text] [Related]
18. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.
Schinke C; Giricz O; Li W; Shastri A; Gordon S; Barreyro L; Bhagat T; Bhattacharyya S; Ramachandra N; Bartenstein M; Pellagatti A; Boultwood J; Wickrema A; Yu Y; Will B; Wei S; Steidl U; Verma A
Blood; 2015 May; 125(20):3144-52. PubMed ID: 25810490
[TBL] [Abstract][Full Text] [Related]
19. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
[TBL] [Abstract][Full Text] [Related]
20. TRIM31 promotes acute myeloid leukemia progression and sensitivity to daunorubicin through the Wnt/β-catenin signaling.
Xiao Y; Deng T; Ming X; Xu J
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32232394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
